Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
Seres Therapeutics (MCRB) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/02/21
Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative ColitisBusiness Wire • 03/02/21
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdatesBusiness Wire • 03/02/21
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular TargetPRNewsWire • 02/25/21
Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021Business Wire • 02/24/21
Earnings Preview: Seres Therapeutics (MCRB) Q4 Earnings Expected to DeclineZacks Investment Research • 02/22/21
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone SymposiumBusiness Wire • 01/19/21
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal GastroenterologyBusiness Wire • 01/06/21
Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/09/20
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdatesBusiness Wire • 11/09/20
Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative ColitisBusiness Wire • 11/06/20
Seres Therapeutics to Host Third Quarter 2020 Financial Results and Operational Progress Conference Call and Webcast on November 9, 2020Business Wire • 11/02/20
Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D.Business Wire • 10/22/20
Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting Business Wire • 10/12/20
Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics SummitBusiness Wire • 09/22/20